BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSI-938: Preliminary Phase I data

Preliminary data from 8 patients in the first cohort of the second part of a Phase I trial showed that 300 mg PSI-938 once daily for 14 days resulted in a median HCV RNA change of 5.23 log10 IU/mL from baseline. HCV RNA remained below the...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >